[stock_ticker symbols=”CTTH” show=”” number_format=”” decimals=”” static=”” speed=”” class=””]

September 13, 2018 in Industry News, Top News

Aurora Cannabis Converts CTT Pharmaceuticals Debenture into 9% Equity Position

September 11, 2018 10:08 ET | Source: CTT Pharmaceutical Holdings, Inc. Companies Working on Regulatory Approval for CTT’s Sublingual Wafer Technology Hamilton, Ontario, Sept. 11, 2018 (GLOBE NEWSWIRE) -- CTT…
Read More
Our Vision


Improve the overall quality of life for patients by providing safe, flexible, simple and innovative drug delivery systems for pain management therapies and treatments.

Our overall mandate is to develop fast dissolving oral thin film wafers of opioids and medical marijuana for treatment of chronic pain, post operative surgical pain, arthritis and joint pain.

Most fast dissolving systems on the market today deliver anti-inflammatories, antihistamines and cough and breath related medications. CTT believes that its technology could gain widespread use in major markets such as Pain Management (MedWafe), Medicinal Marijuana (Cannawafe), as well as Veterinary Medicine (VetWafe).

How it Works